My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    RS-127445
    RS-127445

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0968
    CAS #: 199864-87-4Purity ≥98%

    Description: RS-127445 (RS 127445; RS127445) is a novel, potent, selective, and orally bioavailable 5-HT2B receptor antagonist with important biological activity. It inhibits 5-HT2B with a pKi of 9.5 and pIC50 of 10.4, and exhibits >1000-fold selectivity for 5-HT2B over other 5-HT receptors. 

    References: Br J Pharmacol. 1999 Jul;127(5):1075-82; Neurogastroenterol Motil. 2010 Feb;22(2):e69-76.

    Related CAS#: 199864-86-3 (HCl)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)281.33
    FormulaC17H16FN3
    CAS No.199864-87-4
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 56 mg/mL (199.1 mM)
    Water: <1 mg/mL
    Ethanol: 8 mg/mL (28.4 mM)
    SMILES CodeCC(C1=CC(C2=C3C=CC=CC3=C(F)C=C2)=NC(N)=N1)C
    SynonymsMT500; RS-127445; RS 127445; RS127445; MT-500; MT 500.


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: RS-127445 is a novel high affinity, selective 5-HT2B receptor antagonist devoid of detectable intrinsic activity. RS-127445 is found to have nM affinity and 1000 fold selectivity for the 5-HT2B receptor. RS-127445 is thus among the highest affinity, most selective 5- HT2B receptor ligands. RS-127445 potently blocks the 5-HT evoked increase in inositol phosphate formation and blocks the 5-HT evoked increases in intracellular calcium concentrations with a potency 1000 times greater than that of yohimbine.


    Kinase Assay: The selectivity of RS-127445 for 5-HT2B receptors is examined by testing the compound for affinity at over 100 additional ion channel or receptor binding sites. CHO-K1 cells expressing human 5-HT2A, 5-HT2B or 5-HT2C receptors are harvested using 2 mM EDTA in phosphate buffered saline. Cell membranes are prepared by four cycles of homogenization and centrifugation (48,000×g for 15 min). Each assay is established so as to achieve steady state conditions and to optimize specific binding. For the 5-HT2A receptor, membranes from 1×106 cells are incubated with 0.2 nM [3 H]-ketanserin at 32 °C for 60 min. Nonspecific binding is determined using 10 μM methysergide. For the 5-HT2B receptor, membranes from 1.5×106 cells are incubated with 0.2 nM [3 H]-5-HT at 48 °C for 120 min. Nonspecific binding is determined using 10 μM 5-HT. For the 5-HT2Creceptor, membranes from 3×10 5 cells are incubated with 0.5 nM [3 H]-mesuler -gine at 32 °C for 60 min. Nonspecific binding is determined using 10μM methysergide. Assays are terminated by vacuum filtration through glass fibre filters(GF/B) which has been pretreated with 0.1% polyethyleneimine. Total and bound radioactivity is determined by liquid scintillation counting. Greater than 90% specific binding is achieved in each of these assays.  


    Cell Assay: RS-127445, vehicle or other antagonists are pre-incubated with 240 μl of HEK-293 cells expressing the human 5-HT2B receptor suspension at 37 °C for 20 min. HEK-293 cells are incubated with[3H]-myoinositol (1.67 μCi/ml) in 162 cm2 flasks overnight at 37 °C in an inositol free Ham's F12 medium containing 10% dialyzed foetal bovine serum. The cells are harvested, washed five times with phosphate bufffered saline and resuspended in inositol free Ham's F12 media at density of approximately 3×103 cells/ml. The reactions are initiated by addition of 5-HT. Sixty minutes later, the reactions are terminated by adding 50 μl of ice-cold 20% perchloric acid, chilled in an ice-water bath for 10 min and then neutralized with 160μl of 1 N KOH. Each sample is diluted with 2 ml of 50 mM Tris-HCl, pH 7.4 at room temperature. The aqueous portion (2.2 ml) is transferred onto Dowex AG1X8 columns (1 ml, 1 : 1, w/v) which has been washed with 5 ml of distilled water. The columns are then washed with 18 ml of distilled water and the inositol phosphates are eluted with 3 ml of 1 N HCl. The eluted radioactivity is determined by liquid scintillation spectroscopy using a Packard 1900CA analyzer.

    In VivoRS-127445 is readily absorbed with no obvious dose or route-dependent limitations and rapidly absorbed following both oral and intraperitoneal administration with peak plasma concentrations being achieved within 15 min of dosing. RS-127445 concentration in the plasma are proportional to the administered dose. RS-127445 administrated at dose of 5 mg/kg with approximately 60% of an intraperitoneal dose and 14% of the oral dose is bioavailable. RS-127445 concentration in the plasma is predicted to fully saturate accessible 5-HT2B receptors can be readily achieved and maintained in the rat. RS-127445 administered at 1 to 10 mg/kg with oral significantly inhibits visceral hypersensitivity up to 35 to 74% provoked by restraint stress. Oral RS-127445 produces a significant suppression of TNBS-induced visceral hypersensitivity (15 to 62% inhibition at 3 to 30 mg/ kg), although RS-127445 has no significant effect on the visceral nociceptive threshold of native rats. RS-127445 administrated orally with 1 to 30 mg/kg also dose -dependently reduce the restraint stress-induced defecation in native and TNBS-treated rats. RS-127445 inhibits colonic motility and defecation. 
    Animal modelRats
    Formulation & DosageDissolved in  ethanol:pro-pylene glycol : water (10 : 50 : 40, v/v/v); 5 mg/kg; Oral for 2.5 h ,intraperitoneal and intravenousroutes for 0.08 h 
    References

    Br J Pharmacol. 1999 Jul;127(5):1075-82; Neurogastroenterol Motil. 2010 Feb;22(2):e69-76


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    RS-127445

    (A) 5-HT mediated stimulation of inositol phosphate formation in the presence of ascending concentrations of RS-127445. Each data point is the means±s.e.mean of 12 different determinations. (B) Schild regression of the data in A. Br J Pharmacol. 1999 Jul;127(5):1075-82.
     

    RS-127445

    (A) Effects of 5-HT and RS-127445 on intracellular calcium concentrations in HEK-293 cells expressing the human 5-HT2B receptor. Each data point is the means±s.e.mean of four (RS-127445) or eleven (5-HT) different determinations. (B) Inhibition of 5-HT (10 nM) evoked increases in intracellular calcium concentrations by RS-127445, mianserin and yohimbine. Br J Pharmacol. 1999 Jul;127(5):1075-82.
     

    RS-127445

    (A) Inhibition of 5-HT-evoked contraction of the rat isolated stomach fundus by ascending concentrations of RS-127445. Each data point is the means±s.e.mean of at least three different determinations. (B) Schild regression analysis of the data in A. Br J Pharmacol. 1999 Jul;127(5):1075-82.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?